TGen News & Press Releases

Circulating Tumor DNA Guides Chemotherapy Use in Stage II Colon Cancer

Posted Saturday June 4, 2022

Researchers from TGen, a part of City of Hope, contribute to study supporting value of ctDNA in assessing treatment options

TGen study offers path for late-stage cancer patients wanting to leverage their own health data to guide their care

Posted Wednesday May 18, 2022

TGen works with Arizona zoos and state and federal wildlife agencies to test wild animals for SARS-CoV-2, the causative agent of COVID-19 in humans

Posted Monday May 16, 2022

Program helps ensure animals and the general public are protected from SARS-Cov-2 and serves as a model for monitoring other zoonotic diseases in the future

TGen, ASU, NAU, UArizona and ADHS compile 100,000 sequenced genomes of COVID

Posted Tuesday May 3, 2022

Arizona COVID-19 Genomics Union positions state to play a role in CDC’s national pathogen genomics strategy

TGen recognizes Lynda Carter Altman and the Salt River Pima-Maricopa Indian Community at its annual Founders Dinner

Posted Thursday April 21, 2022

Wendy’s® franchisee’s Jr. Frosty® fundraiser benefits TGen cancer research

Posted Monday April 4, 2022

Fundraising starts today at nearly 200 Wendy’s in 10 states, including more than 60 locations across Arizona

TGen-Temple review suggests even normal weight individuals are susceptible to severe fatty liver disease

Posted Thursday March 24, 2022

Risk factors could include diet, genetics and ethnicity; no global consensus on how to screen for potentially deadly liver conditions

Could diet modification make chemotherapy drugs more effective for patients with pancreatic cancer?

Posted Monday March 21, 2022

Laboratory experiments at Princeton University and TGen, testing a ketogenic diet, lead to nationwide clinical trial

TGen, HonorHealth and Irish biomedical team initiate promising ‘Nieto’ clinical trial against pancreatic cancer

Posted Friday March 18, 2022

Named for a respected Arizona scientist, this trial uses a combination of drugs against advanced cancer in patients where other treatments have failed

‘Purple Pansies’ donates $1 million in support of TGen pre-clinical study

Posted Wednesday February 23, 2022

Disrupting cancer cells’ ability to formulate proteins could open door to improved treatment of pancreatic cancer

Prev
1
[2]
3
4
5
Next

Media Contact

Galen Perry
[email protected]
602-343-8423

News Archive

View Media Release Archive

TGen is a partner with OncLive

Media Contact

Newsletter

News Archive

Latest Posts

Useful Links

Contact Us

Stay up-to-date with TGen